Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Mustang Bio ( (MBIO) ) is now available.
On July 7, 2025, Mustang Bio announced that the FDA granted Orphan Drug Designation for its MB-101 CAR T-cell therapy targeting IL13Ra2 for treating recurrent diffuse and anaplastic astrocytoma and glioblastoma. This designation, along with a previous one for MB-108, validates Mustang’s approach of combining MB-101 with MB-108 to enhance treatment efficacy by reshaping the tumor microenvironment. The designation provides incentives like tax credits and market exclusivity, potentially strengthening Mustang’s position in the biopharmaceutical industry.
Spark’s Take on MBIO Stock
According to Spark, TipRanks’ AI Analyst, MBIO is a Underperform.
Mustang Bio’s overall stock performance is hindered by significant financial instability, including zero revenues and continuous losses. While technical indicators suggest bearish momentum, the recent asset sale to AbbVie provides a glimmer of hope for cost reduction. However, the lack of earnings call data limits insights into future guidance, further emphasizing the need for caution.
To see Spark’s full report on MBIO stock, click here.
More about Mustang Bio
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers. The company aims to acquire rights to these technologies through licensing or ownership, fund research and development, and bring these technologies to market, often partnering with top medical institutions to advance CAR-T therapies.
Average Trading Volume: 5,725,127
Technical Sentiment Signal: Sell
Current Market Cap: $14.62M
See more insights into MBIO stock on TipRanks’ Stock Analysis page.